Diagnosing MS can be a challenge and misdiagnosis can lead to unnecessary and potentially harmful risks. We report on a study of 110 people who were misdiagnosed, which identified migraine and fibromyalgia as some of the conditions most frequently misdiagnosed as MS.
We report on a phase II trial of a new drug called amiselimod, which indicates that the drug is effective and safe in patients with relapsing–remitting MS.
We also feature a study showing that hormone replacement therapy in postmenopausal women with MS was associated with better physical quality of life.
We report on the results of a detailed analysis of MRI outcomes from two phase III trials which compare alemtuzumab with subcutaneous interferon b-1a in MS. The study shows that alemtuzumab is superior to the interferon on MRI outcomes in relapsing remitting MS.
Finally we feature a study using optical coherence tomography to monitor changes in the retina as a marker of MS activity.
Dr Dhia Chandraratna
Head of international scientific and medical research